Overdiagnosis of atypical lipomatous tumors/well-differentiated liposarcomas by morphological diagnosis using only HE stained specimens: a case–control study with MDM2/CDK4 immunostaining and MDM2/CDK4 fluorescence in situ hybridization
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Overdiagnosis of atypical lipomatous tumors/well-differentiated liposarcomas by morphological diagnosis using only HE stained specimens: a case–control study with MDM2/CDK4 immunostaining and MDM2/CDK4 fluorescence in situ hybridization ; volume:24 ; number:1 ; day:21 ; month:11 ; year:2024 ; pages:1-9 ; date:12.2024
BMC cancer ; 24, Heft 1 (21.11.2024), 1-9, 12.2024
- Urheber
-
Nomura, Kentaro
Tomita, Masato
Kuroda, Kishio
Souda, Masakazu
Chiba, Ko
Yonekura, Akihiko
Osaki, Makoto
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-024-13215-4
- URN
-
urn:nbn:de:101:1-2502072118007.747254762994
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:36 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Nomura, Kentaro
- Tomita, Masato
- Kuroda, Kishio
- Souda, Masakazu
- Chiba, Ko
- Yonekura, Akihiko
- Osaki, Makoto
- SpringerLink (Online service)
Ähnliche Objekte (12)
CDK4 inhibition diminishes p53 activation by MDM2 antagonists
Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas
Amplification of CDK4 and MDM2: a detailed study of a high-risk neuroblastoma subgroup
PDLIM7 and CDH18 regulate the turnover of MDM2 during CDK4/6 inhibitor therapy-induced senescence
CDK4 is co-amplified with either TP53 promoter gene fusions or MDM2 through distinct mechanisms in osteosarcoma
Low-Grade Uterine Adenosarcoma with Overexpression of MDM2 and CDK4 by Immunohistochemistry: A Case Report and Literature Review
MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer
Regulation of CDK4
Impact of the MDM2 splice-variants MDM2-A, MDM2-B and MDM2-C on cytotoxic stress response in breast cancer cells
The MDM2 gene family
Analysis of the genomic and protein status of MDM2 and CDK4 in a multiphenotypic tumour with co-existing lines of lipogenic and osteogenic differentiation
Inhibition of MDM2 homodimerization by XIAP IRES stabilizes MDM2, influencing cancer cell survival
CDK4 inhibition diminishes p53 activation by MDM2 antagonists
Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas
Amplification of CDK4 and MDM2: a detailed study of a high-risk neuroblastoma subgroup
PDLIM7 and CDH18 regulate the turnover of MDM2 during CDK4/6 inhibitor therapy-induced senescence
CDK4 is co-amplified with either TP53 promoter gene fusions or MDM2 through distinct mechanisms in osteosarcoma
Low-Grade Uterine Adenosarcoma with Overexpression of MDM2 and CDK4 by Immunohistochemistry: A Case Report and Literature Review
MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer
Regulation of CDK4
Impact of the MDM2 splice-variants MDM2-A, MDM2-B and MDM2-C on cytotoxic stress response in breast cancer cells
The MDM2 gene family
Analysis of the genomic and protein status of MDM2 and CDK4 in a multiphenotypic tumour with co-existing lines of lipogenic and osteogenic differentiation
Inhibition of MDM2 homodimerization by XIAP IRES stabilizes MDM2, influencing cancer cell survival
CDK4 inhibition diminishes p53 activation by MDM2 antagonists
Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas
Amplification of CDK4 and MDM2: a detailed study of a high-risk neuroblastoma subgroup
PDLIM7 and CDH18 regulate the turnover of MDM2 during CDK4/6 inhibitor therapy-induced senescence
CDK4 is co-amplified with either TP53 promoter gene fusions or MDM2 through distinct mechanisms in osteosarcoma
Low-Grade Uterine Adenosarcoma with Overexpression of MDM2 and CDK4 by Immunohistochemistry: A Case Report and Literature Review
MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer
Regulation of CDK4
Impact of the MDM2 splice-variants MDM2-A, MDM2-B and MDM2-C on cytotoxic stress response in breast cancer cells
The MDM2 gene family
Analysis of the genomic and protein status of MDM2 and CDK4 in a multiphenotypic tumour with co-existing lines of lipogenic and osteogenic differentiation